Alabama is currently home to 1232 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958
Recruiting
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan live longer overall and without the cancer getting worse compared... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: USA Mitchell Cancer Institute ( Site 4142), Mobile, Alabama
Conditions: Endometrial Cancer
Register for Updates
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
NCT06104280
Recruiting
Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel interven... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Opioid Use Disorder, Sleep Disturbance
Register for Updates
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT06099769
Recruiting
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Metastatic Breast Cancer
Register for Updates
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
NCT06047886
Recruiting
Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation procedure. In such settings standard immune suppression strategies are avoided due to their myelosuppressive nature. Therefore those patients are at increased risk of graft versus host disease, and the infusion of a CD34 selected graft would reduce such a risk. The infusion of CD34 selected graft using CliniMACS plus is currently FDA FDA-app... Read More
Gender:
ALL
Ages:
Between 4 weeks and 75 years
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: AML, ALL, Lymphoid Malignancies, Myelodysplastic Syndromes, CML, Primary Myelofibrosis
Register for Updates
Internet-Based Lifestyle Intervention (iLIVE) to Eradicate Obese Frailty in Prostate Cancer Survivors
NCT06011499
Recruiting
This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Alabama, Birmingham, Alabama
Conditions: Prostate Carcinoma
Register for Updates
Investigating Dynamic Interactions in Distributed Cognitive Control Networks
NCT05927974
Recruiting
The purpose of this study is to investigate the brain activity associated with cognitive tasks (thinking, reasoning, remembering) in order to understand how the brain works during certain tasks and to improve treatment for diseases like dementia and attention deficit disorders. Cognitive (thinking) impairment may include poor memory function, poor attention span, or psychiatric disorders (ex: ADD, depression). The investigators are interested in the brain activity related to these issues, and wa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cognitive Impairment, Dementia, ADD, Depression
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
04/09/2025
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama
Conditions: Atopic Dermatitis
Register for Updates
A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
NCT05879718
Recruiting
The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: * are adults of 18 years of age or older. * are confirmed to have CLE or SLE with involvement of the skin. * have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2025
Locations: The Kirklin Clinic of UAB Hospital, Birmingham, Alabama
Conditions: Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288
Recruiting
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
04/09/2025
Locations: Research Site 30001-287, Mobile, Alabama
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153
Recruiting
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/09/2025
Locations: Trinity Research Group, Dothan, Alabama
Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Huntsville, Alabama
Conditions: Generalized Anxiety Disorder
Register for Updates
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418
Recruiting
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates